Table 1.
CDA reinforces immune regulation to attenuate antitumor responses
| Group | CDA | Co-treatment (with CDA) |
Induced ICP pathways | Outcomes | ||||||
| Survival* | Relapse† | Immunity | ||||||||
| αPD-1 | IDOi | COX2i | PD-L1 | IDO | COX2 | |||||
| A | – | 0/46 | – | |||||||
| B | + | + | + | + | 11/47 | 0/11 | 0/11‡ | |||
| C | + | + | + | + | 15/15 | 15/15 | – | |||
| D1 D2 D3 |
+ + + |
1MT NLG BMS |
+ + + |
+ + + |
5/8 4/8 14/14 |
0/2 0/4 14/14 |
– | |||
| E | + | + | BMS | 8/9 | 8/8 | – | ||||
| F1 F2 |
+ + |
+ + |
+ + |
- - |
15/15 8/9 |
0/15 0/8 |
15/15‡ 8/8§ |
|||
| G | + | Small LLC tumors (~100 mm3) | 15/15 | 0/15 | 15/15‡ | |||||
Numbers represent total number of mice from combined experiments.
*No. of mice surviving to end point (>60 days).
†No. of mice with tumors at end points (day 60 for groups A-F1, day 30 for group F2).
‡No. of mice resistant to LLC re-challenge at day 60.
§No. of mice resistant to primary and distal tumor growth (abscopal effects).
CDA, cyclic diadenyl monophosphate; COX2i, cyclooxygenase-2 inhibitor; ICP, immune checkpoint; IDOi, indoleamine 2,3 dioxygenase inhibitor; LLC, Lewis lung carcinoma; PD-1, programmed death-1; PD-L1, programmed death ligand-1.